PSEN2 and DDX5 were upregulated, whereas ITPKB was downregulated, in the AD-treated group, with the effects being amplified by the use of the combination medication, indicating that the modulation of AD gene expression was possible with Augmentin treatment. The gene discussed is DDX5; the disease is Alzheimer disease.